Armata Reports $54.9M Q3 Net Income on $69.6M Loan Fair-Value Gain
Armata reported Q3 2026 net income of $54.9 million, compared with a $26.7 million net loss in Q3 2025. The result was primarily driven by a $69.6 million convertible-loan fair-value gain. Its planned AP-SA02 Phase 3 study is expected to begin in H2 2026, subject to FDA protocol concurrence.
Armata reported Q3 2026 net income of $54.9M, versus a $26.7M net loss in Q3 2025, primarily driven by a $69.6M convertible-loan fair-value gain. The planned AP-SA02 Phase 3 study is expected to begin in H2 2026, subject to FDA protocol concurrence.Material DetailsContext by AI AnalystThis is a lat…